Overview

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Status:
Unknown status

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

Reduced intensity conditioning followed by allogeneic stem cell transplantation will result in mixed/complete donor chimerism and potentially alter the natural history and outcome of patients with non-malignant diseases.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Columbia University

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate
Vidarabine